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Objectives: In resource-limited settings, it is a challenge to get quality clinical specimens due to poor infrastruc-
ture for their collection, transportation, processing and storage. Using dried blood spots (DBS) might be an
alternative to plasma for HIV-1 drug resistance testing in this setting. The objectives of this study were to deter-
minemutationsassociatedwithantiretroviralresistanceamongchildren,18 monthsoldborntoHIV-1-infected
mothers enrolled in prevention of mother-to-child transmission services in northern Tanzania.
Patients and methods: Kilimanjaro Christian Medical Center (KCMC) Clinical Laboratory is the zonal centre for
early infant diagnosis using DBS in northern Tanzania. DBS were collected from January 2011 to December
2012. Mothers were kept on triple therapy and single-dose nevirapine before pregnancy and during labour,
respectively. Infants were given single-dose nevirapine and most of them were breastfed. Genotypic resistance
was determined in those with a viral load of .400 copies/mL.
Results: Genotypic resistance mutations were detected in 13 of 46 children (28%). HIV-1 genotypes were
A1 (n¼27), C (n¼10), A/D (n¼4), D (n¼3) and CRF10_CD (n¼2). The median age was 12 weeks (IQR 6–28).
The mean log10 viral load was 3.87 copies/mL (SD 0.995). All major mutations were detected in the reverse
transcriptase gene and none in the protease gene region. The most frequent mutations were Y181C (n¼8)
and K103N (n¼4), conferring resistance to non-nucleoside reverse transcriptase inhibitors.
Conclusions: One-third of infants newly diagnosed with HIVi nn o r t h e r nT a n z a n i ah a r b o u r e dm a j o rd r u g
resistance mutations to currently used antiretroviral regimens. These mutations were detected from DBS
collected from the ﬁeld and stored at room temperature. Surveillance of drug resistance among this population
in resource-limited settings is warranted.
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Introduction
Globally, 3.4 million children were living with HIV at the end of
2011, of which 91% reside in sub-Saharan Africa. The majority
acquired HIV from their HIV-infected mothers during preg-
nancy, birth or breastfeeding. Transmission of HIV from mother
to child can be effectively prevented by timely provision
of antiretroviral treatment (ART) to the mother.
1 However,
scaling up of prevention of mother-to-child transmission
(PMTCT) services towards zero paediatric infection by 2015, as
recommended by the WHO, comes with many challenges in
low- and middle-income countries.
2 Important obstacles to
effective PMTCT are late detection of mothers in need of ART,
lack of reliable HIV tests for infants, limited laboratory capacity
to detect treatment failure and lack of paediatric antiretroviral
formulations.
3
Expansion of ARTprogrammes in resource-limited settings has
radically changed the face of the HIV/AIDS pandemic; however,
there is an increasing need for surveillance of transmitted
drug-resistant HIV.
4 There are limited data on genotypic resist-
ance results from DBS collected from the ﬁeld environment in
sub-Saharan Africa. So far, only two studies have been done in
Tanzania using DBS to determine genotype data. No study has
been conducted on ART drug resistance mutations obtained
from DBS collected for the purpose of early infant diagnosis
from children ,18 months in the country.
5–7 Furthermore, chal-
lenges in rural settings are more pronounced due to a shortage
of well-trained health workers, cold chain facilities, transportation
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1928and other logistics of service deliveries.
8 Therefore, we aimed to
determine HIV drug resistance (HIVDR) in children ,18 months
of age born to HIV-1-infected mothers enrolled in PMTCTservices
using DBS in northern Tanzania.
Patients and methods
From January 2011 to December 2012, a retrospective cross-sectional
study was carried out among children ,18 months old born to
HIV-1-infected mothers. This is the group of children diagnosed during
early infant diagnosis using DNA PCR technology to avoid false positive
as a result of maternal antibodies. These exposed children were given
single-dose nevirapine syrup as prophylaxis to protect them from mater-
nal viral infection. Dried blood spots (DBS) with two or more saturated
spots were considered eligible. Ethical clearance was sought and granted
by the Kilimanjaro Christian Medical College review board followed by the
Botswana–Harvard partnership for approval of the material transfer
agreement. Mothers and caregivers provided consent before collection
of DBS. We used 122 DBS cards from HIV-1-positive children collected
from four regions, namely Kilimanjaro, Manyara, Arusha and Tanga.
These DBS were collected according to guidelines from the National
AIDS Control Programme. Positive PCR DBS were shipped from the
Kilimanjaro Christian Medical University College Clinical Laboratory to the
Botswana–Harvard Partnership HIV Research Laboratory for analysis.
RNA was extracted from two circles of DBS using the NucliSENS silica-
based extraction method (bioMe ´rieux, Durham, NC, USA) according to the
manufacturer’s instruction. DBS specimens for HIV viral load were
analysed using NucliSENS EasyQ HIV-1 v2.0 Analyzer (bioMe ´rieux,
Canada) with a lower detection limit of 20 copies/mL. Specimens with a
viral load of .400 copies/mL were subjected to RT–PCR followed by
nested PCR. We ampliﬁed the entire protease (PR) region and a portion
of the reverse transcriptase (RT) region, representing 1.6 kb of HIV-1 pol.
Sequencing was done using a 16 capillary 3130 XL ABI Prism Genetic
Analyzer sequencer (Applied Biosystems, Foster City, Canada).
Sequencher version 5.0 premier DNA software was used to edit raw
sequences manually and form a contig in fasta format ﬁle, which was
thensubmitted totheStanford HIVDrugResistanceDatabaseforanalysis.
To determine HIV-1 subtypes, the REGA HIV-1 and HIV-2 automated sub-
typingtoolversion2.0wasusedto assignallsubjects withpureHIV-1sub-
typeasitdiffersfromotherintersubtypes.ThePRandRTforsubtypingand
drug resistance-associated mutations wereinterpreted usingthe Stanford
Genotypic Resistance Interpretation Algorithm for specimens collected
from HIV-1-infected infants and the Calibrated Population Resistance
tool was used.
6 The sequences obtained were submitted to GenBank
under accession numbers KJ482111–KJ482156. The main outcomes of
interestwereHIV-1subtypediversityandmajordrugresistancemutations
to currently used regimens in the region. The data were analysed using
S P S Sv e r s i o n1 6 . 0f o rW i n d o w s( S P S SI n c . ,C h i c a g o ,I L ,U S A ) .A l lt e s t s
were two-sided and the level of signiﬁcance was set at P,0.05.
Results
Out of 640 tested children, 122 had a positive HIV DNA test and
were included in the study. Out of these, 22 (18.03%) DBS were
excluded due to fungal contamination, while 37 (30.32%) were
excluded due to viral load ,400 copies/mL. Twelve (9.84%) failed
ampliﬁcation and 5 (4.10%) had an undetectable viral load. The
mean log10 viral load was 3.87 copies/mL (SD 0.995). The remain-
ing 46 (37.70%) were eligible for subtyping and genotypic testing.
In total, 13 of 46 (28%) children successfully genotyped
exhibited major drug resistance-associated mutations in the RT
gene, of whom 12 had resistance to non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), while one had resistance to both
nucleoside reverse transcriptase inhibitors (NRTIs) and NNRTIs
(Table 1). The most frequent RT mutation was Y181C (n¼8),
which causes high-level resistance to all NNRTIs. K103N (n¼4)
wasthesecond mostcommon RTmutation andcauses high-level
resistance to nevirapine and efavirenz, but not to the newer
NNRTIs etravirine and rilpivirine. Y188L and G190A, which cause
high-level resistance to NNRTIs, were detected in two children.
M184V was detected in one child who was on nevirapine single-
dose syrup prophylaxis. This mutation is speciﬁc for lamivudine-
containing regimens and confers resistance to lamivudine and
emtricitabine. Another interesting ﬁnding was a strain with the
Y181C mutation in a sample collected from a child born to an
HIV-1-infected mother; the mother and child were not kept on
any ART regimen, though they were enrolled with the antenatal
services. Table 2 shows the subjects with detected drug
resistance-associated mutations and the relation to ART prophy-
laxis and breastfeeding. Of concern is one virus strain with
multiclass resistance: Y188L for NNRTIs and M184V for NRTIs.
We also found a case of a transitional mutation, T215S, which is
detected in isolates that eventually go on to develop the NRTI
drug resistance mutations T215Y and T215F.
Discussion
The results from this study demonstrate that nearly one-third of
the transmitted HIV-1 strains had major mutations associated
with antiretroviral drug resistance. At the end of 2013 WHO
recommendsprovisionoflifelongARTforallHIV-positivepregnant
and breastfeeding women in order to prevent mother to child
transmission of HIV, this is known as option B+.I nt h ec u r r e n t
study we showed that NNRTI-associated mutations were pre-
dominant, which means that option A and B for PMTCT (in
which only women with CD4+ Tc e l l s,350 cells/mm
3 or those
with advanced disease were given lifelong ART), despite reducing
vertical transmission of HIV, may lead to the development of
drug-resistant HIV. NNRTI-associated mutations were predomin-
ant, showing that option A and B for PMTCT, despite a reduction in
the vertical transmission of HIV, may lead to the development of
drug-resistant HIV. We excluded many samples because they
were not of good quality according to WHO due to poor storage
conditions, including room temperature in the area with sunlight
exposure.
9 Of the exclusions, 18% were due to fungal contamin-
ation as all samples were stored at room temperature for
6 months. A few samples yielded very short sequences which
might be caused by degradation of nucleic material as they were
at room temperature from collection time to processing time.
The Y181C mutation was detected in two-thirds of the cases
and this mutation causes high-level resistance to nevirapine,
2-fold decreased susceptibility to efavirenz and 5-fold decreased
susceptibility to etravirine and rilpivirine.
9 K103N was the second
most predominant mutation, conferring high-level resistance to
nevirapine and efavirenz. We detected two mutations, Y188L
and G190A, in addition to other NNRTI-associated mutations,
which cause high-level resistance to nevirapine, efavirenz and
rilpivirine. Since NNRTIs are the most widely used ﬁrst-line drugs
inresource-limitedsettings, thesechildren areatriskoftreatment
failure and premature death.
10
Our ﬁndings are in line with a meta-analysis by Arrive et al.,
10
who found NNRTI mutations among 52.6% of HIV-1-exposed
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JACinfants who became infected from mothers who were enrolled in
PMTCT B services. Similar studies from Uganda and Malawi,
among infants infected after single-dose nevirapine, showed
resistance to NNRTI in 50% and 80%, respectively.
11 The most
recent WHO recommendations for PMTCT recommend option
B+,w h e r e a sp l a nAa n dB ,w h i c hw e r eu s e di nt h ec u r r e n t
study, are no longer supported due to the high risk of developing
resistance.
9,11
The mutation M184V was detected in one child who was not
on a regimen containing lamivudine. The mutation was detected
Table 2. Presence of at least one major HIVDR mutation among children infected with different HIV-1 subtypes in northern Tanzania
ID
HIV-1
subtype
Major
mutation(s)
Pre-labour prophylaxis
for mothers
Labour prophylaxis
for mothers
Infant
prophylaxis Mode of feeding
1 A K103N none sdNVP sdNVP exclusively breastfed
2 A K103N ZDV none sdNVP exclusively breastfed
3 A Y181C none none sdNVP alternative feeding
4 A Y181C ZDV none sdNVP exclusively breastfed
5 A Y181C none sdNVP sdNVP alternative feeding
6 A Y181C ZDV sdNVP sdNVP exclusively breastfed
7 A K103N none none sdNVP alternative feeding
8 A Y181C ZDV cART sdNVP exclusively breastfed
9 A Y181C, V75I none none none mixed feeding
10 A Y181C, G190A none sdNVP sdNVP mixed feeding
11 C M184V, Y188L cART cART sdNVP exclusively breastfed
12 C K103N, Y181C none cART none exclusively breastfed
13 D Y181C ZDV cART sdNVP exclusively breastfed
cART, combination antiretroviral treatment, i.e. zidovudine (ZDV)+lamivudine+nevirapine.
sdNVP, single-dose nevirapine, as per Tanzania regimen protocol.
5
Major drug resistance means mutations that by themselves reduce susceptibility to one or more drugs.
20
Table 1. Subjects with at least one HIVDR mutation among children ,18 months of age from northern Tanzania
ID Viral load (copies/mL)
NRTI resistance-associated
mutations
NNRTI resistance-associated
mutations Affected drugs
1 8700 K103N NVP, EFV
2
a 20000 T215S
3 9400 T69D V106I
4 820000 V179T
5 5700 K103N NVP, EFV
6 8300 Y181C ETR
7 38000 Y181C NVP
8 8300 Y181C NVP
9 1200000 Y181C, G190A EFV, NVP
10
b 130000 M184V Y188L NVP, EFV, RPV, 3TC, FTC
11 1400 A71T K103N, Y181C NVP, EFV
12 4000 Y181C NVP
13 99000 K103N NVP, EFV
14 200000 V118I
15 1500 Y181C NVP
16 38000 Y181C NVP
17
b 47000 T69K, V75I/V V106I, Y181C NVP
EFV, efavirenz; ETR, etravirine; FTC, emtricitabine; 3TC, lamivudine; NVP, nevirapine; RPV, rilpivirine.
All major mutations according to the Stanford HIV Database are in bold, whereas underlined mutations are minor mutations. We have also reported
transitional mutations: T215S.
aParticipantwithatransitionalmutation,i.e.anymutationthatbyitselfdoesnotcauseresistancebutthatindicatesevolvingresistance,e.g.RTmutation
T215S can be detected in isolates that go on to develop drug resistance mutations T215Y and T215F.
20
bParticipant having dual-class resistance.
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taininglamivudine,provingthetransmissionofanHIV-1-resistant
strain because this infant was not on lamivudine. This mutation
causes high-level resistance to lamivudine and emtricitabine.
12
Another interesting ﬁnding was a strain with the Y181C mutation
from a child born to an HIV-1-infected mother, both being anti-
retroviral naive. This indicates the occurrence of natural
resistance mutations among drug-naive individuals, as reported
previously in Kilimanjaro. It might result from a transmitted
HIV-1 drug-resistant strain or undisclosed use of ART from the
black market.
13,14 We also detected one virus strain with dual-
class resistance: Y188L for NNRTIs and M184V for NRTIs. The
detection of isolates with T215S in our cohort indicates the
presence of drug selective pressure and strongly suggests resist-
ant viruses.
12
The minor mutations found in the PR are consistent with nat-
urally occurring non-B subtype polymorphisms. The absence of
protease inhibitor resistance in our cohort supports the use of a
protease inhibitor-based ART regimen in HIV-infected children
recently exposed to PMTCT, as recommended by the WHO.
13
Our study has certain limitations. First, the study was small,
which means that the estimates of the proportion of children
with drug resistance might be inexact. Second, the prevalence
of drug resistance in this study might be underestimated because
there is a tendency of fading away from detection with increasing
time from ARTexposure.
15,16
With standard population sequencing we might have missed
some of the resistant strains, because in the absence of ART the
wild-type virus might outgrow the resistant strains.
17–19 Finally,
thefailuretoachievean HIV-1RNAsequencein46of122children
might haveskewedour results;however,itisunlikelythat thiswas
a systematic error affecting our major conclusions.
In summary, we found that drug resistance was common
among children in a routine PMTCT programme in northern
Tanzania. The regimens containing nevirapine, used as a prophy-
laxis for both mothers and infants, put infants at high risk of
subsequent treatment failure. The challenges of using DBS in
resource-limited settings include collection, transportation and
storage conditions in combination with a shortage of healthcare
workers and the long distance to the zonal laboratory, which
might contribute to poor performance. DBS might be very useful
in replacing plasma if WHO protocols for collection and storage
are followed strictly. Our results indicate that there is a need for
surveillance of drug resistance mutations among newly infected
children as well as for improving DBS storage conditions in
Tanzania.
Acknowledgements
We are indebted to the children participating in the study. We
acknowledge the staff at Kilimanjaro Christian Medical Center Clinical
Laboratory, the hospital management, Tanzania Ministry of Health and
Botswana–Harvard HIV Research Laboratory.
Funding
This work was supported by collaborative funds from Fogarty HIV
Research, Training Health Researchers into Vocational Excellence in East
Africa (THRiVE), (grant number 087540) funded by the Wellcome Trust,
Tanzania, Zambia and Botswana consortia (TanZamBo) and the
Kilimanjaro Clinical Research Institute (KCRI).
Transparency declarations
None to declare.
Disclaimers
The ﬁndings and conclusions in this report are those of the authors and do
not necessarily represent the views of the funders.
Use of the trade names is for identiﬁcation only and does not consti-
tute endorsement by the funders.
References
1 Joint United Nations Programme on HIV/AIDS (UNAIDS). Global Report:
UNAIDS Report on the Global AIDS Epidemic 2013. Geneva: UNAIDS, 2013.
2 WHO. World Health Organization Global Strategy for the Surveillance and
Monitoring of HIV Drug Resistance, 2012. Geneva: WHO, 2012.
3 WHO. Antiretroviral Drugs for Treating Pregnant Women and Preventing
HIV Infection in Infants, 2010. Geneva: WHO, 2010.
4 Dineke F, Charles A, Boucher D et al.T e m p o r a lc h a n g e si nt h e
epidemiology of transmission of drug-resistant HIV-1 across the world.
AIDS Rev 2012; 14: 17–27.
5 Somi G, Kibuka T, Diallo K et al. Surveillance of transmitted HIV drug
resistance among women attending antenatal clinics in Dar es Salaam,
Tanzania. Antivir Ther 2008; 13 Suppl 2: 77–82.
6 Johannessen A, Holberg-Petersen M, Lo ¨vgaarden G et al. HIV type-1
drug resistance testing on dried blood spots is feasible and reliable in
patients who fail antiretroviral therapy in rural Tanzania. Antivir Ther
2010; 15: 1003–9.
7 Asgeir J, Carilina G, Natalia Z et al. HIV-1 drug resistance testing from
dried blood spots collected in rural Tanzania using the ViroSeq HIV-1
genotyping system. J Antimicrob Chemother 2011; 66: 260–4.
8 National Aids Control Programme. Tanzania National Guidelines for the
Management of HIV and AIDS. Dar es Salaam, 2012.
9 Victoria A, Vincent C, Huldry F et al. Update of the drug resistance
mutations in HIV-1. Topics Antivir Med 2013; 21: 6–14.
10 Arrive E, Newell ML, Ekouevi DK et al. Prevalence of resistance to
nevirapine in mothers and children after single-dose exposure to prevent
vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:
1009–21.
11 WHO. Antiretroviral Therapy for HIV Infection in Infants and Children:
Towards Universal Access. Recommendations for a Public Health
Approach, 2010. Geneva: WHO, 2010.
12 Yang C, McNulty A, Diallo K et al. Development and application of
broadly sensitive dried-blood-spot-based genotyping assay for global
surveillance of HIV-1 drug resistance. J Clin Microbiol 2010; 48: 3158–64.
13 Kasang C, Kalluvya S, Majinge C et al. HIV drug resistance (HIVDR) in
antiretroviral therapy-naive patients in Tanzania not eligible for WHO
threshold HIVDR survey is dramatically high. PLoS One 2011; 6: e23091.
14 Nyombi BM, Holm-Hansen C, Kristiansen KI et al. Prevalence of reverse
transcriptase and protease mutations associated with antiretroviral drug
resistance among drug-naı ¨ve HIV-1 infected pregnant women in Kagera
and Kilimanjaro regions, Tanzania. AIDS Res Ther 2008; 5: 13.
15 MacLeod IJ, Rowley CF, Thior I et al. Minor resistant variants in
nevirapine-exposed infants may predict virologic failure on nevirapine-
containing ART. J Clin Virol 2010; 48: 162–7.
HIV-1 drug mutations in children from northern Tanzania
1931
JAC16 Persaud D, Ray SC, Kajdas J et al. Slow human immunodeﬁciency virus
type 1 evolution in viral reservoirs in infants treated with effective
antiretroviral therapy. AIDS Res Hum Retroviruses 2007; 23: 381–90.
17 Persaud D, Palumbo P, Ziemniak C et al.E a r l ya r c h i v i n ga n d
predominance of nonnucleoside reverse transcriptase inhibitor-resistant
HIV-1 among recently infected infants born in the United States. J Infect
Dis 2007; 195: 1402–10.
18 Chaix ML, Rouet F, Kouakoussui KA et al. Genotypic human
immunodeﬁciency virus type 1 drug resistance in highly active
antiretroviral therapy-treated children in Abidjan, Cote d’Ivore. Pediatr
Infect Dis J 2005; 24: 1072–6.
19 Bratholm C, Johannessen A, Naman E et al.D r u gr e s i s t a n c ei s
widespread among children who receive long-term antiretroviral
treatment at a rural Tanzanian hospital. J Antimicrob Chemother 2010;
65: 1996–2000.
20 Genotype-Phenotypediscordances-DrugResistanceDatabase.http://
hivdb.stanford.edu/pages/documentPage/genoPheno.html (22 March
2014, date last accessed).
Shao et al.
1932